Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

Dexamethasone 4nelarabine 3Calcium Dobesilate 2terameprocol 1ontuxizumab 1mogamulizumab 1isatuximab 1forodesine 1fludarabine phosphate 1fludarabine 1crenigacestat 1cobomarsen 1calaspargase pegol 1brincidofovir 1Whole-Body Irradiation 1Stem Cell Transplantation 1Sirolimus 1Sensitivity and Specificity 1Ranitidine 1Oxaliplatin 1Mycophenolic Acid 1Mesna 1Lenalidomide 1HBI-8000 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Filgrastim 1Fentanyl 1Diphenhydramine 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × crenigacestat × Clear all
NCT02518113 2019-09-11

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

Eli Lilly and Company

Phase 1/2 Completed
36 enrolled 17 charts
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡